Showing 261-270 of 717 results for "".
Understanding the Role of Herbs in Cosmeceuticals
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/understanding-the-role-of-herbs-in-cosmeceuticals/20445/A unique herb blend in cosmeceuticals has shown clinical superiority over antioxidant and growth factor products.Letter to the Editor
https://practicaldermatology.com/columns/letter-to-the-editor/letter-to-the-editor-2/23905/The Financial Contract Every Practice Must Have... And Very Few Do
https://practicaldermatology.com/topics/practice-management/the-financial-every-practice-must-have-and-very-few-do/21166/Total Body Skin Exams: Don't Abandon Them
https://practicaldermatology.com/topics/skin-cancer-photoprotection/total-body-skin-exams-dont-abandon-them/20628/Lesion-directed exams may save time, but is the limited temporal savings worth it?Asset Protection: A Matter Of Degree
https://practicaldermatology.com/topics/practice-management/asset-protection-a-matter-of-degree/21431/How to protect your personal and professional assets.Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/issues/novemberdecember-2025/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/48891/Primary hyperhidrosis (PH) is a chronic, often underreported and underdiagnosed condition without a cure. While it frequently runs in families, the exact etiology is unknown.Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/topics/rare-disease/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/39946/New in My Practice: OTC Skincare/New Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-skincarenew-products-1/23721/Fringe Benefit Plans: Valuable Planning Tools You Haven't Heard Of
https://practicaldermatology.com/topics/practice-management/fringe-benefit-plans-valuable-planning-tools-you-havent-heard-of/21488/Fringe benefit plans lack many of the restrictions of qualified plans and, therefore, are relatively inexpensive to implement.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.